Dr. Douglas Tremblay, MD
Claim this profileMount Sinai
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
3 reported clinical trials
7 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
FLT3 positive
t(8;21) negative
inv(16) negative
2Acute Myeloid Leukemia
FLT3 positive
t(8;21) negative
inv(16) negative
Affiliated Hospitals
Clinical Trials Douglas Tremblay, MD is currently running
DSP-5336
for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Recruiting1 award Phase 1 & 215 criteria
Pacritinib + Azacitidine
for Leukemia
This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle. Pacritinib will be initially tested at a dose of 200mg twice daily (dose level 0) in combination with azacitidine 75mg/m2, which can be administered subcutaneously or intravenously, for 7 days in a 28-day cycle. If there are 2 DLTs in the first 6 patients, there will be a dose escalation to pacritinib 100mg twice daily (dose level -1) and an additional 6 patients will be enrolled. Based on the phase 1, 3+3 dose de-escalation design, 6-12 patients will be enrolled in the phase 1 portion. After the completion of phase 1 and identification of the recommended phase 2 dose (RP2D), the trial will then proceed to phase 2 which will employ a Simon two stage design. This portion will include the 6 patients enrolled during the phase 1 portion at the MTD. An interim analysis for futility will occur. If 3 or fewer patients have had a clinical benefit (CB) or better, as defined by 2015 MDS/MPN IWG criteria, the PI and DSMC will meet to discuss the totality of the evidence and determine if the trial shall proceed. In the second stage, an additional 12 patients will be enrolled.
Recruiting1 award Phase 1 & 213 criteria
More about Douglas Tremblay, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Douglas Tremblay, MD has experience with
- Cytarabine
- Daunorubicin
- Gilteritinib
- Midostaurin
- DSP-5336
- Azacitidine
Breakdown of trials Douglas Tremblay, MD has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Relapse
Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Douglas Tremblay, MD specialize in?
Douglas Tremblay, MD focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved FLT3 positive patients, or patients who are t(8;21) negative.
Is Douglas Tremblay, MD currently recruiting for clinical trials?
Yes, Douglas Tremblay, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Douglas Tremblay, MD has studied deeply?
Yes, Douglas Tremblay, MD has studied treatments such as Cytarabine, Daunorubicin, Gilteritinib.
What is the best way to schedule an appointment with Douglas Tremblay, MD?
Apply for one of the trials that Douglas Tremblay, MD is conducting.
What is the office address of Douglas Tremblay, MD?
The office of Douglas Tremblay, MD is located at: Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.